Exparel for Postoperative Pain Management in Shoulder Surgery
A Novel Application of Exparel for Postoperative Pain Management in Shoulder Arthroplasty and Humerus Fracture Fixation
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Michigan
-
Dearborn, Michigan, United States, 48124
- Wayne State University Physician Group
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients undergoing shoulder arthroplasty under general anesthesia
- Patients undergoing open reduction internal fixation (ORIF) of a proximal humerus fracture under general anesthesia
- Patients with American Society of Anesthesiologist (ASA) physical status classification of 1-3
- Patients meeting criteria for standard of care continuous peripheral nerve block (CPNB) per anesthesia guidelines.
- Patients agreeing to be available for brief follow up telephone survey post- operatively and being mentally able to respond.
- Patients available for follow up routine post-operative clinic visits, per standard of care.
Exclusion Criteria:
- Contraindications to regional anesthesia
- Significant peripheral neuropathy or neurological disorder affecting the upper extremity
- Contraindication to a component of multimodal analgesia
- Pregnancy
- Opioid tolerance
- Cognitive or psychiatric condition that might affect patient assessment and/or inability to provide informed consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Liposomal Bupivacaine A
One time injection of 1.3% Liposomal Bupivacaine during shoulder arthroplasty
|
local tissue infiltration of Liposomal Bupivacaine during surgery
Other Names:
|
|
Active Comparator: CISB control for A
Peripheral nerve block (CISB) with 0.125% bupivacaine during shoulder arthroplasty .
|
Continues nerve block with Bupivacaine during surgery and postoperatively
Other Names:
|
|
Experimental: Liposomal Bupivacaine B
One time injection of 1.3% Liposomal Bupivacaine during Humerus Fracture Fixation
|
local tissue infiltration of Liposomal Bupivacaine during surgery
Other Names:
|
|
Active Comparator: CISB control for B
Peripheral nerve block (CISB) with 0.125% bupivacaine during fracture fixation
|
Continues nerve block with Bupivacaine during surgery and postoperatively
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Quality of Analgesia
Time Frame: 30 days
|
Quality of analgesia as measured by numerical rating scores for pain (active and at rest) as (0=no pain, 10= worst pain) every two hours for the initial 36 hours, then on day2, day7 and day30 postoperatively
|
30 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Post Operative American Shoulder and Elbow Surgeons (ASES)
Time Frame: Preoperative, 6 weeks and last follow up
|
American Shoulder and Elbow Surgeons (ASES) score is an outcome reporting measure for assessments of shoulder function in patients with shoulder pathology and after shoulder arthroplasty surgery.
ASES is a 100 points scale consisting of two measures: one pain scale (worth 50 points) and 10 activities of daily living(worth 50 points), the total score is the sum of both and the higher total score indicates better outcome.
|
Preoperative, 6 weeks and last follow up
|
|
Subjective Shoulder Value (SSV)
Time Frame: Pre-operative, 6 weeks and last Follow up
|
Functional assessments after shoulder arthroplasty surgery.
The SSV is defined as a patient's subjective shoulder assessment expressed as a percentage of an entirely normal shoulder, which would score 100%.
The range is between 0% and 100%
|
Pre-operative, 6 weeks and last Follow up
|
|
Incidence of Nerve Injury
Time Frame: During hospital stay and at 2 weeks and 6 weeks post-operatively
|
Neuropraxia on the treatment side
|
During hospital stay and at 2 weeks and 6 weeks post-operatively
|
|
Post Operative Opioid Consumption
Time Frame: During hospital stay up to 48 hours after surgery
|
Cumulative amount of opioids administered during the time frame
|
During hospital stay up to 48 hours after surgery
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Postoperative Complications
- Pain
- Neurologic Manifestations
- Fractures, Bone
- Wounds and Injuries
- Shoulder Injuries
- Pain, Postoperative
- Shoulder Fractures
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Sensory System Agents
- Anesthetics
- Anesthetics, Local
- Bupivacaine
Other Study ID Numbers
Other Study ID Numbers
- 2014-193
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.